Search Results - "Kastelein, M"

The 6-year trajectory of non-traumatic knee symptoms (including patellofemoral pain) in adolescents and young adults in general practice: a study of clinical predictors by Kastelein, M, Luijsterburg, P A J, Heintjes, E M, van Middelkoop, M, Verhaar, J A N, Koes, B W, Bierma-Zeinstra, S M A

“…(1) To assess the 1-year and 6-year courses of non-traumatic knee symptoms in adolescents and young adults presenting in general practice. (2) To identify…”
Get more information

Osteoarthritis of the knee at 6-year follow-up and their prognostic factors in patients with traumatic knee complaints in general practice by Kastelein, M, Luijsterburg, P, Koster, I, Verhaar, J, Koes, B, Bierma-Zeinstra, S, Oei, E

Get full text

Osteoarthritis of the knee at 6-year follow-up and their prognostic factors in adults with non-traumatic knee complaints in general practice by Kastelein, M, van de Zande, G, Verhaar, J, Koes, B, Luijsterburg, P, Bierma-Zeinstra, S

Get full text

Compromised LCAT function is associated with increased atherosclerosis by HOVINGH, G. Kees, HUTTEN, Barbara A, HOLLEBOOM, Adriaan G, PETERSEN, Wilma, ROL, Patrick, STALENHOEF, Anton, ZWINDERMAN, Aeilko H, DE GROOT, Eric, KASTELEIN, J. P, KUIVENHOVEN, Jan Albert

“…Prospective epidemiological studies have shown that low plasma levels of HDL cholesterol (HDL-C) are associated with an increased risk for cardiovascular…”
Get full text

Retrospective study of the survival of cats with acquired chronic renal insufficiency offered different commercial diets by Plantinga, E. A., Everts, H., Kastelein, A. M. C., Beynen, A. C.

“…A retrospective study was carried out on the efficacy of seven commercial diets designed to be fed to cats with chronic renal failure. The median survival time…”
Get full text

VCG-BASED ALGORITHM AS COMPARED TO HUMANS EXPERTS: PREDICTION-ACCURACY OF PVC SITE-OF-ORIGIN LOCALIZATION FROM 12-LEAD ECG DATA by Abächerli, R., van Dam, P., Strebel, I., Knecht, S., Spies, F., Kastelein, M., Kühne, M., Sticherling, C., Reichlin, T.

Get full text

The production of L forms of enterococci by HIJMANS, W, KASTELEIN, M J

Get more information

Implicit maneuver coordination: Issues and potential solutions by Kastelein, M. R.

“…In earlier research projects, the depiction of airspace in which a loss of separation is predicted to occur has been explored as a means to increase conflict…”
Get full text

Implicit maneuver coordination: Issues and potential solutions by Kastelein, M. R.

“…Implicit maneuver coordination can be applied to multiple intruders by using conflict areas and location of CPAs. Special scenarios are symmetrical conflicts…”
Get full text

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) by Ballantyne, Christie M., MD, Bays, Harold E., MD, Kastelein, John J., MD, PhD, Stein, Evan, MD, PhD, Isaacsohn, Jonathan L., MD, Braeckman, Rene A., PhD, Soni, Paresh N., MD, PhD

“…AMR101 is an ω-3 fatty acid agent containing ≥96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were…”
Get full text

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial) by Bays, Harold E., MD, Ballantyne, Christie M., MD, Kastelein, John J., MD, PhD, Isaacsohn, Jonathan L., MD, Braeckman, Rene A., PhD, Soni, Paresh N., MD, PhD

“…AMR101 is an omega-3 fatty acid agent containing ≥96% eicosapentaenoic acid ethyl ester and no docosahexaenoic acid. Previous smaller studies suggested that…”
Get full text

A chemically defined medium for the L-phase of group A streptococci by Van Boven, C P, Kastelein, M J, Hijmans, W

Get more information

Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia by Duell, P. Barton, MD, Santos, Raul D., MD, MSc, PhD, Kirwan, Bridget-Anne, PhD, Witztum, Joseph L., MD, Tsimikas, Sotirios, MD, Kastelein, John J.P., MD, PhD

“…Background Familial hypercholesterolemia (FH) is characterized by severely elevated LDL-cholesterol and up to a 20-fold increase in premature cardiovascular…”
Get full text

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial by Kastelein, John J.P., MD, PhD, FESC, Maki, Kevin C., PhD, Susekov, Andrey, MD, Ezhov, Marat, MD, PhD, Nordestgaard, Borge G., MD, DMSc, Machielse, Ben N., MSc, Kling, Douglas, BS, MBA, Davidson, Michael H., MD, FACC

“…Background Omega-3 fatty acids in free fatty acid form have enhanced bioavailability, and plasma levels are less influenced by food than for ethyl ester forms…”
Get full text

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? by Bangalore, Sripal, MD, MHA, Fayyad, Rana, PhD, Kastelein, John J., MD, Laskey, Rachel, PhD, Amarenco, Pierre, MD, DeMicco, David A., PharmD, Waters, David D., MD

“…Abstract Background The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol recommends…”
Get full text

Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease by Shepherd, James, MD, Kastelein, John J.P., MD, PhD, Bittner, Vera, MD, FACC, Deedwania, Prakash, MD, FACC, Breazna, Andrei, PhD, Dobson, Stephen, BSc, Wilson, Daniel J., MD, Zuckerman, Andrea, MD, Wenger, Nanette K., MD, FACC

“…Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study James…”
Get full text

Obesity and Dyslipidemia by Franssen, Remco, MD, Monajemi, Houshang, MD, Stroes, Erik S.G., MD, PhD, Kastelein, John J.P., MD, PhD

“…The alarming and still increasing prevalence of obesity and associated cardiovascular risk raises much concern. The increase in cardiovascular risk depends to…”
Get full text

Beyond Low-Density Lipoprotein Cholesterol by Arsenault, Benoit J., PhD, Rana, Jamal S., MD, PhD, Stroes, Erik S.G., MD, PhD, Després, Jean-Pierre, PhD, Shah, Prediman K., MD, Kastelein, John J.P., MD, PhD, Wareham, Nicholas J., MBBS, PhD, Boekholdt, S. Matthijs, MD, PhD, Khaw, Kay-Tee, MBBChir

“…Objectives This study was designed to test the hypothesis that at any low-density lipoprotein cholesterol (LDL-C) level, other lipid parameters such as…”
Get full text

LOWER: A Registry Evaluating Long-Term Lomitapide Use in Patients with Homozygous Familial Hypercholesterolemia by Underberg, James A., MD, FNLA, Kastelein, John, MD, Larrey, Dominique, Makris, Lukas, Schwamlein, Charles, Blom, Dirk

Get full text

Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms by Verbeek, Rutger, MD, Sandhu, Manjinder S., PhD, Hovingh, G. Kees, MD, PhD, Sjouke, Barbara, MD, Wareham, Nicholas J., MBBS, PhD, Zwinderman, Aeilko H., PhD, Kastelein, John J.P., MD, PhD, Khaw, Kay-Tee, MBBChir, Tsimikas, Sotirios, MD, Boekholdt, S. Matthijs, MD, PhD

“…According to the ACC/AHA definition of CVD, 1,556 participants were defined as case and 15,101 as control. According to the SCORE definition, 414 participants…”
Get full text